ACA
LEGN icon

Atlas Capital Advisors’s Legend Biotech LEGN Stock Holding History

Atlas Capital Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-821
Closed -$55.1K – 909
2023
Q3 		$55.1K Hold
821
– – 0.01% 523
2023
Q2 		$56.7K Buy
+821
New +$53.6K 0.01% 553

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Atlas Capital Advisors's LEGN Position: Q4 2023 in Review

Atlas Capital Advisors sold out of Legend Biotech (LEGN) in Q4 2023, closing a stake of 821 shares — an estimated $55.1K sold.

Atlas Capital Advisors first reported a position in LEGN in Q2 2023 and held it in 2 quarters. The position peaked at $56.7K in Q2 2023. 206 funds tracked by Wall St. Rank hold LEGN as of Q4 2023.

  • Atlas Capital Advisors reported no remaining Legend Biotech position as of Q4 2023 after selling out during the quarter.
  • Atlas Capital Advisors sold 821 Legend Biotech shares in Q4 2023, an estimated $55.1K.
  • Atlas Capital Advisors first reported a position in Legend Biotech in Q2 2023 and held it in 2 quarters.
  • Atlas Capital Advisors's Legend Biotech position peaked at $56.7K in Q2 2023.
  • 206 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2023.

Based on Atlas Capital Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.